Skip to content

View of Cerebral Perfusion in Liver Transplantation

Comparison of Carotid Doppler Ultrasonography With Cerebral Oximetry in Assessing Cerebral Perfusion in Liver Transplantation Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07442214
Acronym
NIRS/Doppler
Enrollment
43
Registered
2026-03-02
Start date
2025-02-01
Completion date
2026-04-15
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Perfusion, End-stage Liver Disease (ESLD), Intraoperative Monitoring, Liver Transplantation

Keywords

End-Stage Liver Disease, Liver Transplantation, Cerebral Perfusion, Intraoperative Monitoring

Brief summary

Investigator's aim in this study is to compare the more accessible and low-cost Carotid Doppler USG measurements, which are relatively more difficult to access, costly, and have technical disadvantages, and to demonstrate their superiority over each other in the evaluation of cerebral perfusion in liver transplantation surgeries, without any invasive intervention to the patient.

Detailed description

Liver transplant surgeries cause intraoperative problems that are difficult to manage from hemodynamic, respiratory, neurological, hematological, and metabolic perspectives due to the nature of liver failure, which affects many organs and systems. Particularly during the anhepatic period, when the healthy graft is integrated into the recipient's vascular system, clamping of the inferior vena cava, one of the two main veins of the hepatic veins, is often required for its connection. This means that a sudden interruption occurs in the blood volume returning to the heart from the lower part of the body, which constitutes half of the total cardiac output. Cerebral perfusion is also affected during the anhepatic period, and previous studies have observed impaired cerebral perfusion using cerebral oximetry. However, not every clinic has a cerebral oximetry device, and there are factors that limit its use. Some of these factors include high cost, hyperbilirubinemia, variables that disrupt regional blood flow, diabetes, hypertension, and low hemoglobin. Ultrasound devices are more commonly available in large clinical centers that perform liver transplant surgeries, even for other purposes. It is possible to evaluate the blood flow to the brain using carotid Doppler ultrasonography. The aim of this study is to measure patients' carotid peak systolic and end-diastolic flow and carotid peak systolic flow variability using carotid Doppler ultrasonography and to compare these measurements with cerebral oximetry measurements. Translated with DeepL.com (free version)

Interventions

DEVICECarotid Doppler Ultrasonography and Near-Infrared Spectroscopy (NIRS)

Non-invasive intraoperative monitoring of cerebral perfusion using NIRS and carotid Doppler.

Sponsors

Inonu University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult patients aged 18-65 years scheduled for elective liver transplantation * Written informed consent obtained prior to participation

Exclusion criteria

* Fulminant hepatic failure * Hepatic encephalopathy * Hepatorenal or hepatopulmonary syndrome * Pre-existing cerebrovascular disease or carotid stenosis * Severe cardiopulmonary comorbidity * Refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
PSvDuring surgery: T0: Preanhepatic phase T1: Anhepatic phase T2: Neohepatic phasepeak systolic velocity (PS) cm/sec)
rSO₂During surgery: T0: Preanhepatic phase T1: Anhepatic phase T2: Neohepatic phaseregional cerebral oxygen saturation (%)

Secondary

MeasureTime frameDescription
PPVDuring surgery: T0: Preanhepatic phase T1: Anhepatic phase T2: Neohepatic phasepulse pressure variation (%)
CIDuring surgery: T0: Preanhepatic phase T1: Anhepatic phase T2: Neohepatic phasecardiac index (L/min/m2)

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026